FY2029 Earnings Estimate for VRDN Issued By Leerink Partnrs

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of Viridian Therapeutics in a report released on Monday, January 27th. Leerink Partnrs analyst T. Smith expects that the company will post earnings of $3.00 per share for the year. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.08 million.

Several other research analysts have also recently weighed in on the company. Royal Bank of Canada raised their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a research note on Tuesday, December 17th. HC Wainwright restated a “buy” rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research report on Monday, December 16th. TD Cowen began coverage on shares of Viridian Therapeutics in a report on Monday, November 25th. They issued a “buy” rating on the stock. Needham & Company LLC reissued a “buy” rating and set a $38.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. Finally, Wells Fargo & Company restated an “equal weight” rating and issued a $27.00 price target (down previously from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $35.70.

Viridian Therapeutics Stock Up 2.5 %

Shares of VRDN stock opened at $18.91 on Tuesday. Viridian Therapeutics has a 1 year low of $11.40 and a 1 year high of $27.20. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The business’s fifty day moving average is $19.45 and its 200-day moving average is $19.36.

Institutional Trading of Viridian Therapeutics

Several large investors have recently added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in shares of Viridian Therapeutics in the fourth quarter worth $26,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Viridian Therapeutics in the 3rd quarter worth about $149,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Viridian Therapeutics in the 3rd quarter worth about $208,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Viridian Therapeutics by 17.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company’s stock worth $318,000 after acquiring an additional 2,036 shares during the period. Finally, AlphaCentric Advisors LLC grew its stake in Viridian Therapeutics by 20.0% during the 3rd quarter. AlphaCentric Advisors LLC now owns 15,000 shares of the company’s stock valued at $341,000 after acquiring an additional 2,500 shares in the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.